Authors:
Amanda Smith, PharmD
Nicole Slater, PharmD, BCACP
Reviewers:
Vivian Cheng, PharmD, BCPS, BCACP
Joseph Nardolillo, PharmD, BCACP
Citation:
Choi JG, Winn AN, Skandari MR, et al. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study. Ann Intern Med. 2022;175(10):1392-1400.
The Problem
You must be logged in to post a comment.
Semaglutide for CKD – Does the FLOW trial impact the standard of care?
Prescription for Savings: The Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the U.S.
Defining the Role of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction
Can Losing Weight Using Semaglutide Prevent a Heart Attack, Ack, Ack, Ack, Ack?
Conquering Confusion: Could Metformin Reduce Dementia Risk?
iForumRx.org is a web-based community of practice designed to inform ambulatory care pharmacy specialists, pharmacy residents, and student pharmacists about high-quality, practice-changing evidence.
Loading ...
Are there any data on an anti-cancer effect with the newer agents (as exist for Metformin)?